CliffBio
biologic

Kimmtrak

tebentafusp-tebn

Loss of exclusivityJanuary 2034projected — 12-year biologic exclusivity estimate
CompanyImmunocore Limited

Drug detail

Brand nameKimmtrak
Active ingredienttebentafusp-tebn
Strength100MCG/0.5ML
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kimmtrak patent cliff — loss of exclusivity January 2034 | CliffBio